BLTE Relative Valuation
BLTE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BLTE is overvalued; if below, it's undervalued.
Historical Valuation
Belite Bio Inc (BLTE) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -35.09. The fair price of Belite Bio Inc (BLTE) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price：151.27
Fair
-65.86
PE
1Y
3Y
5Y
Trailing
Forward
-138.05
EV/EBITDA
Belite Bio Inc. (BLTE) has a current EV/EBITDA of -138.05. The 5-year average EV/EBITDA is -3.62. The thresholds are as follows: Strongly Undervalued below -41.66, Undervalued between -41.66 and -22.64, Fairly Valued between 15.40 and -22.64, Overvalued between 15.40 and 34.42, and Strongly Overvalued above 34.42. The current Forward EV/EBITDA of -138.05 falls within the Strongly Undervalued range.
-56.88
EV/EBIT
Belite Bio Inc. (BLTE) has a current EV/EBIT of -56.88. The 5-year average EV/EBIT is -33.75. The thresholds are as follows: Strongly Undervalued below -52.01, Undervalued between -52.01 and -42.88, Fairly Valued between -24.62 and -42.88, Overvalued between -24.62 and -15.49, and Strongly Overvalued above -15.49. The current Forward EV/EBIT of -56.88 falls within the Strongly Undervalued range.
0.00
PS
Belite Bio Inc. (BLTE) has a current PS of 0.00. The 5-year average PS is 10.80. The thresholds are as follows: Strongly Undervalued below -79.10, Undervalued between -79.10 and -34.15, Fairly Valued between 55.75 and -34.15, Overvalued between 55.75 and 100.71, and Strongly Overvalued above 100.71. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-94.94
P/OCF
Belite Bio Inc. (BLTE) has a current P/OCF of -94.94. The 5-year average P/OCF is -43.63. The thresholds are as follows: Strongly Undervalued below -69.41, Undervalued between -69.41 and -56.52, Fairly Valued between -30.74 and -56.52, Overvalued between -30.74 and -17.85, and Strongly Overvalued above -17.85. The current Forward P/OCF of -94.94 falls within the Strongly Undervalued range.
-90.09
P/FCF
Belite Bio Inc. (BLTE) has a current P/FCF of -90.09. The 5-year average P/FCF is -12.93. The thresholds are as follows: Strongly Undervalued below -52.05, Undervalued between -52.05 and -32.49, Fairly Valued between 6.64 and -32.49, Overvalued between 6.64 and 26.20, and Strongly Overvalued above 26.20. The current Forward P/FCF of -90.09 falls within the Strongly Undervalued range.
Belite Bio Inc (BLTE) has a current Price-to-Book (P/B) ratio of 19.26. Compared to its 3-year average P/B ratio of 14.80 , the current P/B ratio is approximately 30.15% higher. Relative to its 5-year average P/B ratio of 12.93, the current P/B ratio is about 48.95% higher. Belite Bio Inc (BLTE) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -0.42%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -0.35% , the current FCF yield is about -100.00% lower.
19.26
P/B
Median3y
14.80
Median5y
12.93
-0.59
FCF Yield
Median3y
-0.42
Median5y
-0.35
Competitors Valuation Multiple
The average P/S ratio for BLTE's competitors is 0.00, providing a benchmark for relative valuation. Belite Bio Inc Corp (BLTE) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of BLTE increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of BLTE in the past 1 year is driven by Unknown.
People Also Watch
FAQ
Is Belite Bio Inc (BLTE) currently overvalued or undervalued?
What is Belite Bio Inc (BLTE) fair value?
How does BLTE's valuation metrics compare to the industry average?
What is the current P/B ratio for Belite Bio Inc (BLTE) as of Dec 05 2025?
What is the current FCF Yield for Belite Bio Inc (BLTE) as of Dec 05 2025?
What is the current Forward P/E ratio for Belite Bio Inc (BLTE) as of Dec 05 2025?